Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GeneVax IL-12 + HIV pDNA vaccine
- Development stage
- Unknown
- Lead developer
- Aurobindo Pharma
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GeneVax IL-12 + HIV pDNA vaccine is an investigational DNA vaccine combination developed by Auro Vaccines in partnership with the HIV Vaccine Trials Network (HVTN). The vaccine consists of two primary components: a multi-antigen HIV plasmid DNA (pDNA) immunogen encoding several HIV proteins (gag, pol, env, nef, tat, and vif) and GENEVAX® IL-12, a molecular adjuvant comprising a dual-promoter DNA plasmid that encodes the p35 and p40 subunits of human interleukin-12 (IL-12). The IL-12 component is designed to enhance cellular immune responses, specifically CD4+ and CD8+ T cell activity. The vaccine is administered intramuscularly using the Ichor TriGrid™ Delivery System for electroporation to improve cellular uptake. It has been evaluated in several Phase 1 clinical trials (including HVTN 080 and HVTN 087) for the prevention of HIV infection in healthy adults.
- Brand names
- GeneVax™ IL-12 + HIV pDNA vaccineGENEVAX® IL-12
- Other names
- GeneVax IL-12 + HIV pDNA vaccineHIV pDNA vaccine + IL-12 pDNA
02
Targets
Gag (HIV-1 Gag polyprotein)HIV-1 Pol polyproteinNef (HIV-1 Nef)IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on GeneVax IL-12 + HIV pDNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GeneVax IL-12 + HIV pDNA vaccine.